loading page

Effectiveness of XBB.1.5 vaccines against symptomatic SARS-CoV-2 infection in older adults during the JN.1 lineage-predominant period, European VEBIS primary care multicentre study, 20 November 2023--1 March 2024
  • +27
  • Lore Merdrignac,
  • Charlotte Laniece Delaunay,
  • Nuno Verdasca,
  • Lorena Vega Piris,
  • Joan O'Donnell,
  • Noémie Sève,
  • Camino Trobajo-Sanmartín,
  • Silke Buda,
  • Mariette Hooiveld,
  • Ana Paula Rodrigues,
  • Gergő Túri,
  • Neus Latorre-Margalef,
  • Ivan Mlinarić,
  • Mihaela Lazar,
  • Marine Maurel,
  • Daniel Castrillejo,
  • Charlene Bennett,
  • Marie-Anne Rameix-Welti,
  • Iván Martínez-Baz,
  • Ralf Dürrwald,
  • Adam Meijer,
  • Aryse Melo,
  • Beatrix Oroszi,
  • Tove Samuelsson Hagey,
  • Sanja Kurečić Filipović,
  • Frederika Dijkstra,
  • Verónica Gómez,
  • Sabrina Bacci,
  • Marlena Kaczmarek,
  • Esther Kissling
Lore Merdrignac
Epiconcept SAS
Author Profile
Charlotte Laniece Delaunay
Epiconcept SAS
Author Profile
Nuno Verdasca
Instituto Nacional de Saude Doutor Ricardo Jorge Porto
Author Profile
Lorena Vega Piris
Instituto de Salud Carlos III
Author Profile
Joan O'Donnell
Health Protection Surveillance Centre
Author Profile
Noémie Sève
Institut Pierre Louis d'Epidemiologie et de Sante Publique
Author Profile
Camino Trobajo-Sanmartín
Instituto de Salud Publica y Laboral de Navarra
Author Profile
Silke Buda
Robert Koch-Institut
Author Profile
Mariette Hooiveld
Nederlands Instituut voor Onderzoek van de Gezondheidszorg
Author Profile
Ana Paula Rodrigues
Instituto Nacional de Saude Doutor Ricardo Jorge IP Departamento de Doencas Infeciosas
Author Profile
Gergő Túri
Semmelweis Egyetem Egeszsegugyi Menedzserkepzo Kozpont
Author Profile
Neus Latorre-Margalef
Folkhalsomyndigheten
Author Profile
Ivan Mlinarić
Hrvatski zavod za norme
Author Profile
Mihaela Lazar
Institutul Cantacuzino
Author Profile
Marine Maurel
Epiconcept SAS
Author Profile
Daniel Castrillejo
Dirección General de Salud Pública
Author Profile
Charlene Bennett
University College Dublin
Author Profile
Marie-Anne Rameix-Welti
Institut Pasteur Centre Medical
Author Profile
Iván Martínez-Baz
Instituto de Salud Publica y Laboral de Navarra
Author Profile
Ralf Dürrwald
Robert Koch-Institut
Author Profile
Adam Meijer
Rijksinstituut voor Volksgezondheid en Milieu Centrum Infectieziektebestrijding
Author Profile
Aryse Melo
Instituto Nacional de Saude Doutor Ricardo Jorge Porto
Author Profile
Beatrix Oroszi
Semmelweis Egyetem Egeszsegugyi Menedzserkepzo Kozpont
Author Profile
Tove Samuelsson Hagey
Folkhalsomyndigheten
Author Profile
Sanja Kurečić Filipović
Hrvatski zavod za norme
Author Profile
Frederika Dijkstra
Rijksinstituut voor Volksgezondheid en Milieu Centrum Infectieziektebestrijding
Author Profile
Verónica Gómez
Instituto Nacional de Saude Doutor Ricardo Jorge IP Departamento de Doencas Infeciosas
Author Profile
Sabrina Bacci
European Centre for Disease Prevention and Control
Author Profile
Marlena Kaczmarek
European Centre for Disease Prevention and Control
Author Profile
Esther Kissling
Epiconcept SAS

Corresponding Author:e.kissling@epiconcept.fr

Author Profile

Abstract

not-yet-known not-yet-known not-yet-known unknown We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥65 years during the 2023/24 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: -11–48) and 5% (95% CI: -92–56) among those with symptom onset 1–5 , 6–11, and ≥12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.
Submitted to Influenza and other respiratory viruses
Submission Checks Completed
Assigned to Editor
Reviewer(s) Assigned
11 Aug 2024Review(s) Completed, Editorial Evaluation Pending
11 Aug 2024Editorial Decision: Revise Minor
23 Aug 20241st Revision Received
29 Aug 2024Submission Checks Completed
29 Aug 2024Assigned to Editor
29 Aug 2024Editorial Decision: Accept